organophosphonates has been researched along with purvalanol b in 1 studies
| Studies (organophosphonates) | Trials (organophosphonates) | Recent Studies (post-2010) (organophosphonates) | Studies (purvalanol b) | Trials (purvalanol b) | Recent Studies (post-2010) (purvalanol b) |
|---|---|---|---|---|---|
| 9,968 | 880 | 3,596 | 31 | 0 | 13 |
| Protein | Taxonomy | organophosphonates (IC50) | purvalanol b (IC50) |
|---|---|---|---|
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.006 | |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | 0.009 | |
| Cyclin-dependent kinase 1 | Saccharomyces cerevisiae S288C | 1.2 | |
| Insulin receptor | Homo sapiens (human) | 2.2 | |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | 0.006 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.006 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.006 | |
| G2/mitotic-specific cyclin-B | Marthasterias glacialis (spiny starfish) | 0.006 | |
| cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | 3.8 | |
| Cyclin-A2 | Homo sapiens (human) | 0.006 | |
| cAMP-dependent protein kinase catalytic subunit gamma | Homo sapiens (human) | 3.8 | |
| cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | 3.8 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.009 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0072 | |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | 3.3165 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.006 | |
| Cyclin-A1 | Homo sapiens (human) | 0.006 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.006 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.006 | |
| Cdc2 | Patiria pectinifera | 0.15 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.006 | |
| Cyclin-dependent kinase 1 | Oryzias latipes (Japanese medaka) | 0.006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, S; Andrade, L; Bohacek, R; Dalgarno, D; Grossman, T; Jin, L; Keats, J; Keenan, T; MacNeil, I; Metcalf, C; Narula, S; Ram, M; Sawyer, T; Schelling, P; Shakespeare, W; Stehle, T; Sundaramoorthi, R; van Schravendijk, MR; Wang, Y; Weigele, M | 1 |
1 other study(ies) available for organophosphonates and purvalanol b
| Article | Year |
|---|---|
Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
Topics: Adenine; Adenosine Triphosphate; Bone and Bones; Carbon; Catalytic Domain; Cyclin-Dependent Kinase 2; Drug Design; Enzyme Inhibitors; Humans; Ligands; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Models, Molecular; Neoplasms; Nitrogen; Organophosphonates; Protein Conformation; Purines; Pyrimidines; src-Family Kinases; Structure-Activity Relationship; Substrate Specificity | 2006 |